Toregem BioPharma develops a tooth regeneration drug utilizing antibody therapy to stimulate the growth of teeth in patients with congenital tooth loss. This treatment addresses the lack of permanent tooth buds in children, providing a potential solution for dental anomalies such as anodontia and acquired tooth defects.
Funding
$17.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Congenital tooth loss, resulting from a lack of permanent tooth buds, affects a significant portion of the population and can lead to difficulties in chewing, speaking, and overall quality of life. Current treatments often involve temporary solutions like dentures or implants, which do not address the underlying issue of missing teeth. These solutions may require frequent adjustments or replacements and do not offer the benefits of natural teeth.
Solution
Toregem BioPharma is developing an antibody-based drug therapy designed to stimulate tooth regeneration in patients with congenital tooth loss. This innovative approach aims to induce the growth of new, functional teeth by targeting the underlying biological mechanisms responsible for tooth development. The therapy has shown promising results in preclinical studies, demonstrating the potential to restore natural dentition and improve oral health outcomes. By addressing the root cause of tooth loss, Toregem BioPharma seeks to provide a long-lasting and more natural alternative to conventional treatments.
Target Audience
The primary target audience includes individuals with congenital tooth loss, specifically children and adults who lack permanent tooth buds due to genetic factors.
Features
- Antibody-based therapy to stimulate the growth of new teeth
- Targets the biological mechanisms responsible for tooth development
- Designed for patients with congenital tooth loss (anodontia)
- Aims to restore natural dentition and improve oral health
- Preclinical studies have shown promising results